Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918292 · ClinicalTrials.gov registry record · Phase 2
Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT02918292 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 32 participants.
The verdict
NCT02918292, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study is a prospective, multicenter phase II study with patients receiving haploidentical transplantation for Severe Aplastic Anemia (SAA). The primary objective is to assess overall survival (OS) at 1 year post-hematopoietic stem cell transplantation (HSCT).
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- RADIATION Total Body Irradiation (TBI)
- DRUG Antithymocyte Globulin (ATG)
- PROCEDURE Haplo HSCT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-07-03 |
| Est. Completion | 2021-08-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02918292
The ClinicalTrials.gov registry entry for NCT02918292 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02918292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02918292 about?
NCT02918292 is a clinical study titled "Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)". This study is a prospective, multicenter phase II study with patients receiving haploidentical transplantation for Severe Aplastic Anemia (SAA). The primary objective is to assess overall survival (OS) at 1 year post-hematopoietic stem cell transplantation (HSCT).
What is the current status of trial NCT02918292?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2017-07-03. Estimated completion is 2021-08-17.
What interventions are being tested in trial NCT02918292?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Total Body Irradiation (TBI) (RADIATION), Antithymocyte Globulin (ATG) (DRUG), Haplo HSCT (PROCEDURE).
Who is sponsoring clinical trial NCT02918292?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.